Please assess the completion status of the following clinical trial:

Trial Title: Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic hepatitis C (serum HCV-RNA-positive)~* Age 3 to 17 years~* Treatment-naïve~* Platelets \>= 100,000/mm\^3~* Neutrophil counts \>= 1,500/ mm\^3~* TSH must be within normal limits~* Hemoglobin \>=12 g/dL (females); \>=13 g/dL (males)~* Women of childbearing potential must have a routine pregnancy test performed monthly during treatment and for 7 months thereafter. Sexually active female subjects of childbearing potential must be practicing adequate contraception (intrauterine device, oral contraceptives, implanted contraceptives, surgical sterilization, barrier method, or monogamous relationship with a male partner who has had a vasectomy or is using a condom (+ spermicide) during the treatment period and for 7 months after stopping treatment.~* Sexually active male subjects must be practicing acceptable methods of contraception (vasectomy, use of condom + spermicide, monogamous relationship with a female partner who practices an acceptable method of contraception) during the treatment period and for 7 months after stopping treatment.~Exclusion Criteria:~* Contraindications according to the SPC and European approval~* Pretreatment of chronic hepatitis C~* Liver decompensation~* Hypersensitivity to the active substance or to any interferons or to any of the excipients~* Pregnant woman~* Woman who are breast feeding~* Existence of or history of psychiatric condition, in particular depression, suicidal ideation or suicide attempt~* A history of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease in the previous six months~* Severe debilitating medical conditions, including patients with chronic renal failure or creatinine clearance \< 50 mlLmin~* Autoimmune hepatitis or history of autoimmune disease~* Severe hepatic dysfunction or decompensated cirrhosis of the liver~* Pre- existing thyroid disease unless it can be controlled with conventional therapy~* Epilepsy and/or compromised central nervous system function~* Individual decision of physician if patient suitable for treatment (e.g., disturbance of growth)

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- IntronA/Rebetol (Type: None): Children age 3 to 17, with chronic hepatitis C, treated in clinical practice at 10 German sites

Based on this trial design, predict the completion outcome and termination type (if applicable).